Skip to content
The Policy VaultThe Policy Vault

Ukoniq (umbralisib) — Medica

marginal zone lymphoma

Initial criteria

  • age ≥ 18 years
  • patient has received at least one prior anti-CD20-based regimen

Approval duration

3 years